Scarica l'app Stockscreener
40.00
4.37%
1.675
Dopo l'orario di chiusura:
40.42
0.42
+1.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Precedente Chiudi:
$38.33
Aprire:
$38.35
Volume 24 ore:
345.77K
Relative Volume:
0.81
Capitalizzazione di mercato:
$2.26B
Reddito:
-
Utile/perdita netta:
$-80.77M
Rapporto P/E:
-31.50
EPS:
-1.27
Flusso di cassa netto:
$-80.80M
1 W Prestazione:
+11.89%
1M Prestazione:
-0.30%
6M Prestazione:
-18.40%
1 anno Prestazione:
-5.19%
Intervallo 1D:
$38.21
$40.38
Intervallo di 1 settimana:
$35.61
$40.38
Portata 52W:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Nome
Moonlake Immunotherapeutics
Settore
Industria
Telefono
41 41 510 8022
Indirizzo
DORFSTRASSE 29, ZUG
Confronta MLTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
40.00 | 2.26B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-05 | Ripresa | Wedbush | Outperform |
| 2024-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-04-02 | Iniziato | Goldman | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-11-02 | Iniziato | Stifel | Buy |
| 2023-09-14 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Iniziato | Needham | Buy |
| 2023-06-15 | Iniziato | Barclays | Equal Weight |
| 2023-05-01 | Iniziato | Guggenheim | Buy |
| 2023-03-22 | Iniziato | Wedbush | Outperform |
| 2023-03-09 | Iniziato | BTIG Research | Buy |
| 2023-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Iniziato | Bryan Garnier | Buy |
| 2022-11-11 | Iniziato | Jefferies | Buy |
| 2022-08-25 | Iniziato | SVB Leerink | Outperform |
| 2022-07-21 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-07 | Iniziato | Cowen | Outperform |
Mostra tutto
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
(MLTX) On The My Stocks Page - news.stocktradersdaily.com
Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st
Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq
4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World
Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World
MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle
Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia
MoonLake secures up to $500 million financing; research update - The Pharma Letter
Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada
MoonLake secures $500m for lead drug, plus other financings - Pharmaphorum
Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare
MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine
MoonLake secures up to $500M in financing from Hercules Capital - MSN
MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News
MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener
MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord
MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks
MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks
Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener
MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire
MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan
MoonLake (MLTX) Secures $500M Non-Dilutive Financing to Advance Sonelokimab - GuruFocus
How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com
Teacher Retirement System of Texas Has $354,000 Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Long Term Trading Analysis for (MLTX) - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World
PNC Financial Services Group Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - The AM Reporter
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):